Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus COPEGUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus COPEGUS.
ADEFOVIR DIPIVOXIL vs COPEGUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Ribavirin is a nucleoside analogue that inhibits viral RNA synthesis by interfering with RNA capping and polymerase activity, and may also modulate immune responses.
10 mg orally once daily on an empty stomach.
800 mg orally twice daily to 1200 mg orally twice daily based on body weight (≤75 kg: 800 mg; >75 kg: 1200 mg), in combination with ribavirin, for 24 to 48 weeks depending on genotype.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal elimination half-life is approximately 120-170 hours following multiple doses, supporting once-daily dosing with prolonged viral suppression.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Ribavirin is primarily eliminated renally as unchanged drug (61%) and metabolites (30%); biliary/fecal excretion accounts for ~9%.
Category C
Category C
Antiviral
Antiviral